Liver Fibrosis clinical trials
13 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
- LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
- Fibrosis Lessens After Metabolic Surgery
- Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
- Siemens Biomarker Multi-modality
- Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- Endoscopic Ultrasound Shear Wave Elastography Study
- Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues
- Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
- Liver Micro Flow - MRI
- Endosonographic Shear Wave Elastography to Assess Liver and Splenic Fibrosis
- AGED Diagnostics Liver Disease Assessment
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Liver Fibrosis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.